Alpha Tau Medical Ltd Cl A (DRTS)

$6.99 -0.18 (-2.51%)
Market Cap 592.89M
Revenue (ttm) 0.00
Net Income (ttm) -31.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 409,000
Avg Vol 295,496
Day's Range N/A - N/A
Shares Out 84.82M
Stochastic %K 46%
Beta 1.04
Analysts Sell
Price Target $8.67

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 577 4115
Address:
Kiryat HaMada St. 5, Jerusalem, Israel
Newport_menthol_Iover
Newport_menthol_Iover Jan. 26 at 5:37 AM
$DRTS SMELLS LIKE 10 DOLLARS
0 · Reply
OnlyGB
OnlyGB Jan. 25 at 6:37 PM
$DRTS I feel like there are some weekend investors that need to get PUMPED up for Alpha Tau this week!
2 · Reply
JohnStocksNY
JohnStocksNY Jan. 25 at 6:32 PM
$DRTS Also don’t forget to bring the same energy when the Knicks are in the playoffs, now back to the conference championship
0 · Reply
JohnStocksNY
JohnStocksNY Jan. 25 at 6:28 PM
$DRTS I see we got the Football crowd out tonight, don’t forget to bring back all the wager winnings into the stock tomorrow
1 · Reply
kareem1988
kareem1988 Jan. 25 at 6:24 PM
Im with you on $DRTS and 15$, not with the seahawks
1 · Reply
Jessypenny
Jessypenny Jan. 25 at 6:15 PM
Go $DRTS Go seahawks 15$ by weekend
2 · Reply
JohnStocksNY
JohnStocksNY Jan. 25 at 3:34 PM
$DRTS If you’re not with your family or enjoying the outdoors, get some research in. There’s always more to learn about Alpha Tau
0 · Reply
JKtech
JKtech Jan. 25 at 2:36 PM
Small-cap Oncology watch for the DealFlow Discovery Conference in Atlantic City (Jan 28-29). ​Looking for catalysts @ #DealFlow2026. Key management presentations and 1-on-1 meetings to watch: ​ $KAPA (Kairos Pharma): Focused on overcoming drug resistance. Chief Scientific Officer Neil Bhowmick is presenting their structural biology approach to reversing immune suppression in cancer. $DRTS (Alpha Tau): Utilizing Alpha DaRT technology for solid tumors. Momentum building from recent pancreatic trial updates and their targeted alpha-radiation platform. ​$LIXT (Lixte Biotech): Advancing LB-100 as a first-in-class PP2A inhibitor. CEO Geordan Pursglove is holding 1-on-1s to discuss activation lethality in combination therapies. ​$FBLG (FibroBiologics): CEO Pete O’Heeron presents Jan 29 at 11:30 AM. Unique play using fibroblast-derived materials to modify the tumor microenvironment. ​ $PHIO (Phio Pharma): Leveraging the INTASYL pro-RNAi platform to silence genes help tumors evade the immune system.
2 · Reply
WallStWireAds
WallStWireAds Jan. 25 at 9:45 AM
$DRTS https://capnotes.beehiiv.com/p/how-alpha-tau-medical-s-technology-destroys-tumors-without-destroying-the-patient-nasdaq-drts
1 · Reply
JohnStocksNY
JohnStocksNY Jan. 24 at 5:35 PM
$DRTS DealFlow Events today announced Alpha Tau to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City. https://finance.yahoo.com/news/dealflow-discovery-conference-announces-initial-195000828.html?guccounter=1
1 · Reply
Latest News on DRTS
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Jan 23, 2026, 3:34 AM EST - 2 days ago

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 6, 2026, 9:00 AM EST - 19 days ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Jan 5, 2026, 9:00 AM EST - 20 days ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Dec 9, 2025, 9:00 AM EST - 6 weeks ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 4:05 PM EST - 2 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Nov 11, 2025, 8:30 AM EST - 2 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Oct 17, 2025, 10:04 AM EDT - 3 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Oct 16, 2025, 11:55 AM EDT - 3 months ago

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Sep 2, 2025, 8:30 AM EDT - 5 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Alpha Tau to Participate in Five September Investor Conferences

Aug 27, 2025, 8:30 AM EDT - 5 months ago

Alpha Tau to Participate in Five September Investor Conferences

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:02 PM EDT - 5 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jul 25, 2025, 9:04 AM EDT - 6 months ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:01 PM EDT - 8 months ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 12, 2025, 4:01 PM EDT - 9 months ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Alpha Tau to Participate in May Investor Conferences

May 6, 2025, 8:30 AM EDT - 9 months ago

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 9 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 9 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Apr 2, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:02 PM EDT - 11 months ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24, 2025, 8:30 AM EST - 11 months ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:45 AM EDT - 1 year ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 20, 2024, 4:01 PM EDT - 1 year ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 13, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

May 6, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 25, 2024, 8:50 AM EDT - 1 year ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 2 years ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 26, 2024, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 28, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Nov 20, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 16, 2023, 4:30 PM EST - 2 years ago

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Nov 13, 2023, 8:00 AM EST - 2 years ago

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Oct 30, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 28, 2023, 4:02 PM EDT - 2 years ago

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Alpha Tau Medical to Participate in September Investor Conferences

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Alpha Tau Medical to Participate in September Investor Conferences

Newport_menthol_Iover
Newport_menthol_Iover Jan. 26 at 5:37 AM
$DRTS SMELLS LIKE 10 DOLLARS
0 · Reply
OnlyGB
OnlyGB Jan. 25 at 6:37 PM
$DRTS I feel like there are some weekend investors that need to get PUMPED up for Alpha Tau this week!
2 · Reply
JohnStocksNY
JohnStocksNY Jan. 25 at 6:32 PM
$DRTS Also don’t forget to bring the same energy when the Knicks are in the playoffs, now back to the conference championship
0 · Reply
JohnStocksNY
JohnStocksNY Jan. 25 at 6:28 PM
$DRTS I see we got the Football crowd out tonight, don’t forget to bring back all the wager winnings into the stock tomorrow
1 · Reply
kareem1988
kareem1988 Jan. 25 at 6:24 PM
Im with you on $DRTS and 15$, not with the seahawks
1 · Reply
Jessypenny
Jessypenny Jan. 25 at 6:15 PM
Go $DRTS Go seahawks 15$ by weekend
2 · Reply
JohnStocksNY
JohnStocksNY Jan. 25 at 3:34 PM
$DRTS If you’re not with your family or enjoying the outdoors, get some research in. There’s always more to learn about Alpha Tau
0 · Reply
JKtech
JKtech Jan. 25 at 2:36 PM
Small-cap Oncology watch for the DealFlow Discovery Conference in Atlantic City (Jan 28-29). ​Looking for catalysts @ #DealFlow2026. Key management presentations and 1-on-1 meetings to watch: ​ $KAPA (Kairos Pharma): Focused on overcoming drug resistance. Chief Scientific Officer Neil Bhowmick is presenting their structural biology approach to reversing immune suppression in cancer. $DRTS (Alpha Tau): Utilizing Alpha DaRT technology for solid tumors. Momentum building from recent pancreatic trial updates and their targeted alpha-radiation platform. ​$LIXT (Lixte Biotech): Advancing LB-100 as a first-in-class PP2A inhibitor. CEO Geordan Pursglove is holding 1-on-1s to discuss activation lethality in combination therapies. ​$FBLG (FibroBiologics): CEO Pete O’Heeron presents Jan 29 at 11:30 AM. Unique play using fibroblast-derived materials to modify the tumor microenvironment. ​ $PHIO (Phio Pharma): Leveraging the INTASYL pro-RNAi platform to silence genes help tumors evade the immune system.
2 · Reply
WallStWireAds
WallStWireAds Jan. 25 at 9:45 AM
$DRTS https://capnotes.beehiiv.com/p/how-alpha-tau-medical-s-technology-destroys-tumors-without-destroying-the-patient-nasdaq-drts
1 · Reply
JohnStocksNY
JohnStocksNY Jan. 24 at 5:35 PM
$DRTS DealFlow Events today announced Alpha Tau to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City. https://finance.yahoo.com/news/dealflow-discovery-conference-announces-initial-195000828.html?guccounter=1
1 · Reply
McStockpick
McStockpick Jan. 23 at 11:05 PM
$DRTS newb here… looking for info to see if I should get in Any of you hardcore peeps have the 411?
2 · Reply
Newport_menthol_Iover
Newport_menthol_Iover Jan. 23 at 8:49 PM
$DRTS smells like pmda approval
1 · Reply
JohnStocksNY
JohnStocksNY Jan. 23 at 1:42 PM
$DRTS let’s have a beautiful Friday and go into the weekend in style
1 · Reply
OnlyGB
OnlyGB Jan. 23 at 12:52 PM
$DRTS has all the makings of a major move today. The VIX is down. The pre-market is hot. The PMDA could come on Monday. The sellers were blown through. Ask yourself one question: do you own enough $DRTS ? If not, change it ASAP. Fully certified DaRTs means a rocket move.
1 · Reply
kareem1988
kareem1988 Jan. 23 at 12:21 PM
$INTC $DRTS $PLUG $SNDK
0 · Reply
OnlyGB
OnlyGB Jan. 23 at 10:38 AM
$DRTS sexy chart shows volume going up and the price going up and the 20 day moving ave going up and the 50 day moving ave going up and the BUYERS ARE IN CONTROL!!!!
1 · Reply
OnlyGB
OnlyGB Jan. 23 at 10:20 AM
$DRTS Pre-market looks like the sellers are sleeping...
3 · Reply
Jessypenny
Jessypenny Jan. 23 at 9:48 AM
$DRTS Is Heating up 🔥🔥
0 · Reply
DJTEM
DJTEM Jan. 23 at 9:13 AM
$DRTS bullish again 5>10\11$
0 · Reply
Tetroman
Tetroman Jan. 23 at 5:54 AM
$DRTS what’s ur honest price target on approval?
1 · Reply
Runningman79
Runningman79 Jan. 23 at 2:17 AM
$DRTS You can just feel this slow simmering volcanic eruption coming.
0 · Reply
Newport_menthol_Iover
Newport_menthol_Iover Jan. 22 at 11:53 PM
$DRTS smells like 9 dollars
0 · Reply